Assessment of bleeding risk in cancer patients treated with anticoagulants for venous thromboembolic events

Assessment of bleeding risk in cancer patients treated with anticoagulants for venous thromboembolic events

IntroductionAnticoagulant is the cornerstone of the management of VTE at the cost of a non-negligible risk of bleeding. Reliable and validated clinical tools to predict thromboembolic and hemorrhagic events are crucial for individualized decision-making for the type and duration of anticoagulant tre...

Full description

Bibliographic Details
Main Authors: Géraldine Poénou, Emmanuel Tolédano, Hélène Helfer, Ludovic Plaisance, Florent Happe, Edouard Versini, Nevine Diab, Sadji Djennaoui, Isabelle Mahé
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
cancer
venous thromboembolism
bleeding
risk assessment model (RAM)
anticoagulant
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2023.1132156/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2023.1132156/full

Similar Items